In the last trading session, 1.83 million Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares changed hands as the company’s beta touched 1.05. With the company’s per share price at $5.76 changed hands at -$0.65 or -10.14% during last session, the market valuation stood at $334.28M. DNA’s last price was a discount, traded about -726.39% off its 52-week high of $47.60. The share price had its 52-week low at $5.00, which suggests the last value was 13.19% up since then. When we look at Ginkgo Bioworks Holdings Inc’s average trading volume, we note the 10-day average is 1.53 million shares, with the 3-month average coming to 1.67 million.
Analysts gave the Ginkgo Bioworks Holdings Inc (DNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.83. If we narrow down to specifics, the data shows that 2 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended DNA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Instantly DNA was in red as seen at the end of in last trading. With action 1.77%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -41.34%, with the 5-day performance at 1.77% in the green. However, in the 30-day time frame, Ginkgo Bioworks Holdings Inc (NYSE:DNA) is -17.12% down. Looking at the short shares, we see there were 9.98 million shares sold at short interest cover period of 4.85 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6.5, meaning bulls need an upside of 11.38% from its current market value. According to analyst projections, DNA’s forecast low is 4.35 with 12 as the target high. To hit the forecast high, the stock’s price needs a -108.33% plunge from its current level, while the stock would need to tank 24.48% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -27.97%. The 2025 estimates are for Ginkgo Bioworks Holdings Inc earnings to increase by 49.93%, but the outlook for the next 5-year period is at 44.11% per year.
DNA Dividends
Ginkgo Bioworks Holdings Inc is expected to release its next quarterly earnings report on 2025-Feb-24.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.59% of Ginkgo Bioworks Holdings Inc shares while 79.82% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 85.46%. There are 79.82% institutions holding the Ginkgo Bioworks Holdings Inc stock share, with VIKING GLOBAL INVESTORS LP the top institutional holder. As of 2024-06-30, the company held 6.9686% of the shares, roughly 143.09 million DNA shares worth $47.83 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.9327% or 138.96 million shares worth $46.46 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . With 1.17 shares estimated at $6.73 million under it, the former controlled 2.55% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 1.40% of the shares, roughly 640.67 shares worth around $3.69 million.
